9
Participants
Start Date
November 30, 2014
Primary Completion Date
December 13, 2017
Study Completion Date
March 19, 2018
Focal Laser Treatment
All subjects receiving PRN IVT aflibercept injections will be evaluated for focal laser treatment beginning at week 12 through the end of the study. If the subject meets any of the criteria for focal laser treatment (FLT), fluorescein angiography (FA) will be performed to guide the focal laser treatment. Focal laser treatment and focal laser re-treatment will be administered no more than once every 90 days.
aflibercept 2.0 mg
If a subject has recurrent CR-DME they will receive an IVT aflibercept injection
Regeneron Pharmaceuticals
INDUSTRY
Northern California Retina Vitreous Associates
OTHER